DWC202301 + amoxicillin + clarithromycin

DWC202301 + amoxicillin + clarithromycin is a **fixed-dose combination** regimen consisting of the investigational agent DWC202301, along with the antibiotics amoxicillin and clarithromycin. Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis; clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis. Both are commonly used in combination regimens to eradicate *Helicobacter pylori* infections, with various randomized trials showing high efficacy for triple therapy including these agents and a proton pump inhibitor[2][4][6]. The exact nature and mechanism of DWC202301 is undetermined based on current public information; it is likely an investigational drug or adjuvant added to this combination, possibly to enhance efficacy or overcome resistance.